Applikon to buy HaloteC’s biotech portfolio
Bioreactor systems vendor Applikon Biotechnology has arranged to acquire the biotech portfolio of Dutch instruments and software provider HaloteC Instruments.
Applikon CEO Arthur Oudshoorn said the company plans to use the HaloteC technology to augment its existing its bioreactor software offerings.
“Organisations are looking for software solutions to allow parallel processing of bioreactor systems and to process the large amount of data generated by these processes,” he said.
Oudshoorn added that the investment forms part of Applikon’s efforts to be able to provide an advanced data centre for biotech processes.
Terms of the transaction were not disclosed.
Applikon Biotechnology is headquartered in the Netherlands and in Belgium. In Australia and New Zealand, the company provides its products through its dedicated agent Enztech in New South Wales.
Over-the-counter medications linked to antibiotic resistance
Over-the-counter medications such as ibuprofen and paracetamol are quietly driving antibiotic...
Subtle heart dysfunction detected in young adults with bipolar
A new study reveals that myocardial dysfunction is already evident in patients with bipolar...
Prenatal pesticide exposure linked to brain abnormalities
Researchers have reported a link between prenatal exposure to a widely used insecticide and...
